Comparative Pharmacology
Head-to-head clinical analysis: AZELEX versus FINACEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELEX versus FINACEA.
AZELEX vs FINACEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelaic acid inhibits microbial protein synthesis and reduces the proliferation of Propionibacterium acnes. It also normalizes keratinization and has anti-inflammatory effects by scavenging free radicals.
Azelaic acid inhibits microbial protein synthesis, reduces reactive oxygen species production, and modulates keratinocyte and melanocyte function.
Apply a thin layer to affected areas twice daily (morning and evening) or as directed by a physician. Topical use only.
Apply a pea-sized amount topically twice daily (morning and evening) to affected areas of the face.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function; prolonged to 3-4 hours in renal impairment.
Not determined clinically due to negligible systemic absorption; after topical application, plasma levels are below quantification limits; no terminal half-life is established.
Primarily renal (~60% as unchanged drug and metabolites) and biliary/fecal (~40%).
Renal: primarily as unchanged drug (minimal metabolism); approximately 16% of a topical dose is absorbed and excreted renally; fecal excretion is negligible.
Category C
Category C
Topical Acne Agent
Topical Acne Agent / Rosacea Treatment